Key statistics
On Friday, CSL Ltd (CSL:ASX) closed at 276.47, 7.93% above its 52-week low of 256.15, set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 277.13 |
---|---|
High | 278.81 |
Low | 275.00 |
Bid | 276.45 |
Offer | 276.56 |
Previous close | 273.72 |
Average volume | 708.48k |
---|---|
Shares outstanding | 484.21m |
Free float | 483.71m |
P/E (TTM) | 32.68 |
Market cap | 132.54bn AUD |
EPS (TTM) | 8.37 AUD |
Annual div (ADY) | 3.97 AUD |
---|---|
Annual div yield (ADY) | 1.45% |
Div ex-date | Sep 09 2024 |
Div pay-date | Oct 02 2024 |
Data delayed at least 20 minutes, as of Nov 22 2024 05:10 GMT.
More ▼
- Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
- Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
- Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma